# US 11,007,263 B2 · Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,007,263 B2
- Document ID: US11007263B2
- Status: Granted
- Kind: B2
- Application number: 16/580,058
- Filed: 2019-09-24
- Published: 2021-03-25
- Granted: 2021-05-18
- Earliest claimed: 2019-09-24
- Assignees: The United States of America as represented by the Secretary of Agriculture
- Applicants: The United States of America, as represented by the Secretary of Agriculture
- Inventors: Douglas P. Gladue; Manuel V. Borca
- Web page: https://patentgrep.com/patent/US11007263B2

## CPC

- A61K 39/12: Viral antigens
- A61P 31/20: for DNA viruses
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2710/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-GΔI1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.

## Claims

### Claim 1

A genetically modified virus, wherein the virus genome comprises a viral genome at least 95% identical to SEQ ID NO: 2.

### Claim 2 (depends on 1)

The virus of claim 1, wherein the virus genome comprises a viral genome at least 99% identical to SEQ ID NO: 2.

### Claim 3 (depends on 1)

The virus of claim 1, wherein the viral genome comprises SEQ ID NO:2.

### Claim 4 (depends on 1)

A vaccine composition against African Swine Fever Virus (ASFV), comprising the genetically modified virus of claim 1, wherein the ASFV is ASFV-Georgia 2007 isolate (ASFV-G).

### Claim 5 (depends on 1)

A method for the protection of swine against ASFV-G, comprising administering to a swine a live attenuated vaccine comprising the genetically modified virus of claim 1 in an amount effective to protect said swine from clinical ASFV-G disease.

### Claim 6

A recombinant ASFV mutant virus, comprising a synthetic mutation in the I177L open reading frame or in a regulatory element controlling the expression of the I177L protein, resulting in a non-functional genomic I177L gene, wherein the mutant ASFV comprises a genome at least 95% identical to SEQ ID NO: 2.

### Claim 7 (depends on 6)

The recombinant virus of claim 6, wherein the mutant ASFV comprises a genome at least 99% identical to SEQ ID NO: 2.